Pharm Pulmonary Exam 1 Flashcards
LABA
Long acting beta agonist
SABA
Short acting Beta agonist
Most effective medication for relief of acute bronchospasm.
More than one canister per month suggests inadequate asthma control
Regularly scheduled use is not generally recommended
May lower effectiveness
May increase airway hyperresponsiveness
LAMA
Long acting Muscarinic Antagonists
Bronchodilators MOA
Activate Beta 2 receptors in smooth muscles of lung, promoting bronchodilation and thereby relieving bronchospasm.
Also suppress histamine release in the lung and increase ciliary motility
Open up bronchial tubes so that more air can move through.
Helps clear mucus from lungs.
As airway opens the mucus moves more freely and can be coughed out.
Short acting Bronchodilators
Quick acting, Rescue
Relieve asthma symptoms very quickly by opening airways
Action starts within minutes after inhalation and last for 2 to 4 hours
Used 15- 20 minutes before exercise to prevent exercise induced asthma
Long acting Bronchodilators
Used to provide control -
not quick relief of asthma
Lasts for at least 12 hours
Those containing formoterol begin their action within a few minutes, while those containing salmeterol take up to 45 minutes to begin their action
Regularly scheduled of use of SABA is not generally recommended due to:
May lower effectiveness
May increase airway hyperresponsiveness
Albuterol HFA
Ventolin (beta 2 agonist)
Indications
Bronchospasm
Exercise induced bronchospasm (2 puffs 15 minutes before exercise)
(Nebules, Syrup, Inhal soln 0.5%)
Interactions:
Avoid MAOI, tricyclics within 14 days (increased cardiovascular effects)
Adverse:
Hypokalemia,
Tremor, nervousness, headache, dizziness, hyperactivity, insomnia, weakness, tachycardia
Bronchodilators Adverse effects
Inhaled:
(tachycardia, angina, tremors)
Oral:
Systemic exposure is much larger
adverse effects are more likely
Excessive dosage can lead to angina pectoris, tachydysrhythmia, tremor
Ipratropium Bromide
Atrovent 17mcg
(Anti-cholinergic / Anti-muscarinic)
Bronchospasm associated with chronic bronchitis and emphysema Asthma exacerbation (mod-severe)
Contra:
Allergy to atropine or its derivatives
Warning:
Narrow angle glaucoma
Interactions:
Other anti-cholinergics
Adverse:
Anti-cholinergic effects
Ipratropium Bromide 20mcg
+
Albuterol 100mcg
Combivent
Contraindications:
Atropine allergy
Extreme caution within 2 weeks of MAOI’s or tricyclics (increased cardiovascular effect)
Muscarinic antagonist MOA
Ipratropium
Tiotropium (longer acting)
Given by aerosol
Competitively blocks muscarinic receptors in the airways and effectively prevent the bronchoconstriction caused by vagal discharge. it has no effect on the inflammatory aspect of asthma
MDI vs DPI
MDI
Metered Dose inhaler
Advantages -Non breath activated
Disadvantages - Patient coordination
DPI
Dry Powder Inhaler
Advantages - Breath activated, propellent not required
Inhaled corticoid steroids
Mometasone Fluticasone Flunisolide Ciclesonide Budesonide
LABA Adverse / Contras
Formoterol, Salmeterol
For: Bronchospasm
Adverse:
HA, pain, HTN, Dizzy, Nasal/throat irritation
Interactions
Alpha blocker, azoles, BB, Clarithromycin, Loops, MAOI’s, TCA’s, Quinidine, Nelfinavir/ritonavir
Precautions:
CVD, DM, COPD, Thyroid, glaucoma, seizure, hypokalemia, pregnancy, lactation,
Contra:
Acute asthma attack
LABA Medications
Pure LABA’s
Salmeterol
Formoterol
LABA’s
Indacaterol
Oldaterol
Vilanterol
Salmeterol
Adjunct to inhaled corticosteroids for the treatment of asthma in prevention of bronchospasm in reversible airway obstruction disease
Not for acute relief of bronchospasm
Contra:
***Treatment of asthma without use of inhaled corticosteroids
Primary treatment of status asthmaticus
Acute asthma, COPD
Warning
***Asthma related death
Using LABA alone to treat asthma:
When using LABA alone to treat asthma without inhaled corticosteroids can lead to lung inflammation and an increased risk of asthma related death.
LABA + ICS Meds
Advair
Fluticasone + Salmeterol
Airduo
Fluticasone + Salmeterol
Breo Ellipta
Fluticasone + vilanterol
Dulera
Mometasone + formoterol
Symbicort
Budesonide + Formoterol
LTRA
Leukotriene receptor antagonist
Montelukast
Zileuton
Anti-leukotriene agents inhibit the action of leukotrienes by blocking the CysLT1 receptor or by interrupting production by 5-lipoxygenase
LTRA
Leukotriene receptor antagonist
Anti-leukotriene agents inhibit the action of leukotrienes by blocking the CysLT1 receptor
What meds?
Montelukast
Zafirlukast
Pranlukast
MZP
Generally well tolerated
Be aware of possible psych , behavior, neurogenic issues
LTRA
Leukotriene receptor antagonist
by interrupting production by 5-lipoxygenase
Zileutron
Generally has more adverse effects than the others
Montelukast
Singulair (leukotriene receptor antagonist)
> 15 years old : One 10mg tablet
For seasonal allergic rhinitis. Reserve use for those who have an adequate response or intolerance to alternate therapies
Warning:
Serious neuropsychiatric events
Adverse:
URI, Fever, HA, Pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis
Zileuton
Zyflo (5-lipooxygenase inhibitor)
Prophylaxis and chronic treatment of asthma
Not recommended for Children
Contra:
Active liver disease, ALT elevated 3x normal limit
Warnings:
Not for primary treatment of acute attacks
Monitor liver function
History of liver disease, Monitor liver function 1st 3 months, every 2-3 months for remainder of the year
Alcohol consumption, neuropsych events
Interactions Potentiates theophylline (reduce dose of theophylline)
Acute bronchiolitis
is broadly defined as a clinical syndrome of respiratory distress that occurs in children <2 years of age and is characterized by upper respiratory symptoms leading to lower respiratory infection with inflammation, which results in wheezing and or crackles. It typically occurs with primary infection or reinfection with a viral pathogen.
Acute bronchiolitis
management of severe bronchiolitis
Supportive care
(hydration, O2, Resp support)
and anticipatory guidance are the mainstays of management of severe bronchiolitis
Acute bronchiolitis
Children with first episode of bronchiolitis
Don’t administer inhaled bronchodilators
(albuterol, Epi) to infants and children with first episode of bronchiolitis.
Children with RSV bronchiolitis
Treated the same as children with bronchiolitis caused by other pathogens
Supportive care is mainstay
Pharmacotherapy is not routinely recommended
Adults and Older Children with RSV bronchiolitis
Glucocorticoids and bronchodilators may be beneficial
Interventions that have shown a reduced rate of progression and decreased mortality in observational studies include
Single agent combination therapy with ribavirin
intravenous immune globulin
palivizumab
and/or glucocorticoids
Ribavirin
Virazole (Nucleoside analogue)
indications
Sever lower respiratory infections due to RSV in hospitalized infants and young children
Children;
Treat within first 3 days of infection
Contra:
Pregnancy Cat X
palivizumab
Synagis
Class:
Antiviral monoclonal antibody (IgG1K)
Acute epiglottitis
Describes inflammation of the epiglottitis and adjacent supraglottic structures
Airway is first priority
Sniffing, tripod posture
Swelling is generally improved after 2-3 days after ABX when caused by H. Flu
Acute epiglottitis Tx
Combination of
3rd gen ceph
and anti-staph agent (vanc)
Ceph and vanc
Croup (mild)
Single dose Dexamethasone or prednisolone
Children with moderate croup
Stridor at rest with mild to moderate retractions should be evaluated in the office or the ED
Tx: Nebulized Epi
and
Single dose of dexamethasone
0.6mg/kg (max 16mg) least invasive route
Children with severe croup
Stridor at rest with marked retractions and significant distress or agitation should be seen in the ED
Approach these children cautiously as anxiety may increase and worsen the airway obstruction
Tx: Nebulized Epi
and
Single dose of dexamethasone
0.6mg/kg (max 16mg) least invasive route
Why dexamethasone for moderate to severe croup
Most extensively studied inexpensive easy to administer longer duration of action compared with other agents 0.6mg/kg (max 16mg) least invasive route
Hospital management of croup
Supportive care IV fluids, Fever reduction Repeated doses of nebulized EPI Humidified O2 (no repeated dosages of steroids) Monitor for worsening respiratory distress
Pertussis in infants and children
Supportive care is mainstay
Pay attention to fluid and nutritional status
Avoid known triggers for paroxysmal coughing fits
(Exercise, cold, nasopharyngeal suctioning)
Symptomatic treatments with Bronchodilators, corticosteroids, antihistamines, antitussives haven’t been proven to improve cough in pertussis
Pertussis in infants and children
Treatment
Macrolides (Azithromycin, erythromycin)
Bactrim may be used as alternative
For incompletely immunized children with well documented pertussis infection:
Treatment
Complete immunization with an acellular pertussis containing vaccine
DTAP or TDAP vaccine rather than just diphtheria toxoid/tetanus toxoid vaccine
Children may return to school after they have completed 5 days of ABX or if untreated, 21 days after symptoms begin